ConductScience.org, home

Paper23239809

Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.

Minami D and 9 others. Mol Cancer Res, 2013. Cited by 53 papers, by iCite.

Cite this record

ConductScience Library. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Papers, record 23239809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23239809

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.
PubMed
Journal
Mol Cancer Res
PubMed
Year
2013
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
53
iCite
Relative citation ratio, by iCite
1.35
iCite
Revised in PubMed
2016-11-25
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Minami DDaisuke
2Takigawa NNagio
3Takeda HHiromasa
4Takata MMinoru
5Ochi NNobuaki
6Ichihara EEiki
7Hisamoto AAkiko
8Hotta KKatsuyuki
9Tanimoto MMitsune
10Kiura KKatsuyuki

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
CisplatinMajor topic
Lung NeoplasmsMajor topic
PTEN PhosphohydrolaseMajor topic
PhthalazinesMajor topic
PiperazinesMajor topic
Animals
Cell Line, Tumor
DNA Damage
DNA Repair
Drug Synergism
Female
Humans
Mice
Mice, Nude
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerases
Transfection
Xenograft Model Antitumor Assays

Source PubMed

Download CSV of topics

Cited by33

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 53 citations.

PMIDTitleJournalYearIn PapersSource
39201255An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.Int J Mol Sci2024https://conductscience.org/library/papers/39201255PubMed
39085400Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations.NPJ Precis Oncol2024https://conductscience.org/library/papers/39085400PubMed
38873997Polydatin, a potential NOX5 agonist, synergistically enhances antitumor activity of cisplatin by stimulating oxidative stress in non‑small cell lung cancer.Int J Oncol2024https://conductscience.org/library/papers/38873997PubMed
38496700Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review.Transl Lung Cancer Res2024https://conductscience.org/library/papers/38496700PubMed
38323288Novel dual action PARP and microtubule polymerization inhibitor AMXI-5001 powerfully inhibits growth of esophageal carcinoma both alone and in combination with radiotherapy.Am J Cancer Res2024https://conductscience.org/library/papers/38323288PubMed
37077938RAB27B Drives a Cancer Stem Cell Phenotype in NSCLC Cells Through Enhanced Extracellular Vesicle Secretion.Cancer Res Commun2023https://conductscience.org/library/papers/37077938PubMed
35018214Transcriptomics reveals in vivo efficacy of PARP inhibitor combinatorial synergy with platinum-based chemotherapy in human non-small cell lung carcinoma models.Oncotarget2022https://conductscience.org/library/papers/35018214PubMed
34335884Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells.Exp Ther Med2021https://conductscience.org/library/papers/34335884PubMed
32860347Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene.J Cell Mol Med2020https://conductscience.org/library/papers/32860347PubMed
32801835Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes.Pharmgenomics Pers Med2020https://conductscience.org/library/papers/32801835PubMed
31717544PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target.Cancers (Basel)2019https://conductscience.org/library/papers/31717544PubMed
31423128Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid.EXCLI J2019https://conductscience.org/library/papers/31423128PubMed
30889466Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation.Redox Biol2019https://conductscience.org/library/papers/30889466PubMed
30831275Cationic lipoplexes for treatment of cancer stem cell-derived murine lung tumors.Nanomedicine2019https://conductscience.org/library/papers/30831275PubMed
29579325A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.Cancer2018https://conductscience.org/library/papers/29579325PubMed
29448954New therapeutic strategies to treat human cancers expressing mutant p53 proteins.J Exp Clin Cancer Res2018https://conductscience.org/library/papers/29448954PubMed
28886696Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.BMC Cancer2017https://conductscience.org/library/papers/28886696PubMed
28577239Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.Cancer Chemother Pharmacol2017https://conductscience.org/library/papers/28577239PubMed
27655368Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?Clin Transl Oncol2017https://conductscience.org/library/papers/27655368PubMed
27308587Trial watch - inhibiting PARP enzymes for anticancer therapy.Mol Cell Oncol2016https://conductscience.org/library/papers/27308587PubMed

See all 33 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CHEK11111PubTator's text mininghttps://conductscience.org/library/genes/1111NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
MRE114361PubTator's text mininghttps://conductscience.org/library/genes/4361NCBI Gene
PARP1142PubTator's text mininghttps://conductscience.org/library/genes/142NCBI Gene
PTEN5728PubTator's text mininghttps://conductscience.org/library/genes/5728NCBI Gene
RAD515888PubTator's text mininghttps://conductscience.org/library/genes/5888NCBI Gene
RPA16117PubTator's text mininghttps://conductscience.org/library/genes/6117NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23239809

GET https://conductscience.org/api/papers/v1/23239809/cited_by?page=2